Skip to main content
logo
Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
134.28
0.00 (0.00%)
At close: Jul 27, 2026, 4:00 PM EDT
134.28
0.00 (0.00%)
After-hours: Jul 27, 2026, 4:10 PM EDT

Apogee Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Net Income
-274.62-255.84-182.15-83.99
Depreciation & Amortization
1.621.420.19-
Stock-Based Compensation
52.3146.2823.336.1
Other Adjustments
-2.87-3.82-10.55-2.98
Changes in Accounts Payable
-1.210.15-1.071.61
Changes in Accrued Expenses
0.96-1.076.297.65
Changes in Other Operating Activities
-10.73-14.55-7.22-3.16
Operating Cash Flow
-234.54-227.45-171.17-74.76
Operating Cash Flow Growth
----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Capital Expenditures
-0.83-5.15-1.15-0.17
Purchases of Investments
-727.34-642.3-649.45-303.74
Proceeds from Sale of Investments
500.27467.87350.1430
Investing Cash Flow
-227.91-179.57-300.46-273.91

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Issuance of Common Stock
10.3396.49495.11315.39
Net Common Stock Issued (Repurchased)
10.3396.49495.11315.39
Financing Cash Flow
807.04396.49495.11315.39

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Net Cash Flow
344.59-10.5323.47-33.28

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-235.37-232.6-172.33-74.93
Free Cash Flow Growth
----
Free Cash Flow Per Share
-3.70-3.83-3.12-3.00
Levered Free Cash Flow
-284.53-275.05-185.11-78.05
Unlevered Free Cash Flow
-315.46-304.49-219.81-87.07
SEC Filings: 10-K · 10-Q